Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YYB101 in advanced solid tumors
NCT02499224Phase 1Completed
- Sponsor
- CellabMED
- Start
- Jul 2015
- Primary completion
- Jul 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yyb101 in solid tumor, sponsored by CellabMED. Primary endpoints: Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Jul 2015; status: completed.
02
Drugs
yyb101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02499224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499224.